Skip Navigation

European Heart Journal 2000 21(7):591-593; doi:10.1053/euhj.2000.2059
Copyright © 2000 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gietzen, F.H.
Right arrow Articles by Khun, H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Gietzen, F.H.
Right arrow Articles by Khun, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Letters to the Editor

A reply

F.H. Gietzen, CH.J. Leuner, J. Hegselmann, C. Strunk-Mueller and H. Khun

Bielefeld Hospital, University of Münster, Bielefeld, Germany

References

  1. Gietzen FH, Leuner ChJ, Raute-Kreinsen U. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J. 1999;20:1342–1354[Abstract/Free Full Text]
  2. Maron BJ. New interventions for obstructive hypertrophic cardiomyopathy: promise and prudence. Eur Heart J. 1999;20:1292–1294[Free Full Text]
  3. Maron BJ, Bonow RO, Cannon RO, Leon MB, Epstein SE. Hypertrophic cardiomyopathy: Interrelations of clinical manifestations, pathophysiology, and therapy. N Engl J Med. 1987;316:780–789[Web of Science][Medline]
  4. Spirito P, Seidman CE, McKenna WJ, Maron BJ. Medical progress: The management of hypertrophic cardiomyopathy. N Engl J Med. 1997;336:775–785[Free Full Text]
  5. Schulte HD, Gramsch-Zabel H, Schwartzkopff R. Hypertrophic obstructive cardiomyopathy (HOCM): surgical management. Schweiz Med Wochenschr. 1995;125:1940–1949[Web of Science][Medline]
  6. Robbins RC, Stinson EB. Long-term results of left ventricular myotomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg. 1996;111:586–594[Abstract/Free Full Text]
  7. Maron BJ, Merrill WH, Freier PA, Kent KM, Epstein SE, Morrow AG. Long-term clinical course and symptomatic status of patients after operation for hypertrophic subaortic stenosis. Circulation. 1978;57:1205–1213[Abstract/Free Full Text]
  8. Faber L, Seggewiß H, Strick S, Bogunovic N, Gleichmann U. Intra-procedural myocardial contrast echocardiography: a routine procedure in percutaneous transluminal septal myocardial myocardial ablation in hypertrophic obstructive cardiomyopathy (Abstr). Eur Heart J. 1998;19:12[Web of Science][Medline]
  9. Borggrefe M. Ergebnisse zur Hochfrequenzstromablation der atrioventriculären Überleitung. Borggrefe M. Katheterablation tachykarder Herzrhythmusstörungen mittels Hochfrequenzstrom. : Steinkopff Darmstadt; 1994. p. 58–61
  10. Faber L, Seggewiss H, Fassbender D, Strick S, Schmidt HK, Gleichmann U. Risk factors for permanent trifascicular block after PTSMA for HOCM. Circulation. 1997;96:I-645
  11. Lakkis NM, Nagueh SF, Kleimann NS. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation. 1998;98:1750–1755[Abstract/Free Full Text]
  12. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Results with respect to intraprocedural myocardial contrast echocardiography. Circulation. 1998;98:2415–2421[Abstract/Free Full Text]
  13. Kuhn H, Gietzen FH, Schäfers M. Changes in the left ventricular outflow tract after transcoronary ablation of septal hypertrophy (TASH) for hypertrophic obstructive cardiomyopathy as assessed by transoesophageal echocardiography and by measuring myocardial glucose utilization and perfusion. Eur Heart J. 1999;20:1808–1817[Abstract/Free Full Text]
  14. Kuhn H, Gietzen F, Jachmann B, Gockel B, Freick M. Die Bedeutung der Belastungsdopplerechokardiographie bei HOCM für die Behandlung mittels transkoronarer Ablation der Septum Hypertrophie (TASH). (Abstract). Z Kardiol. 1999;88:I-687[CrossRef]
  15. Kizilbash AM, Heinle SK, Grayburn PA. Spontaneous Variability of left ventricular outflow tract gradient in hypertrophic obstructive cardiomyopathy. Circulation. 1998;97:461–466[Abstract/Free Full Text]
  16. Rosing DR, Condit JR, Maron BJ. Verapamil Therapy: A new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III. Effects of long-term administration. Am J Cardiol. 1981;48:545–553[CrossRef][Web of Science][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gietzen, F.H.
Right arrow Articles by Khun, H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Gietzen, F.H.
Right arrow Articles by Khun, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?